Chapter 2

Aging and β-Cell Proliferation, Molecular and Signaling Changes and What This Means for Targeted Regeneration

Aaron R. Cox


Increased age confers a greater risk for the development of type 2 diabetes (T2D), and also has significant consequences for β-cell growth and regeneration. Pancreatic insulin-producing β-cells are long-lived, and exhibit very little turnover in adult life. The severe decline in β-cell proliferation contributes to a decreased capacity for β-cell regeneration with age. β-cell regeneration is dependent on mitogenic signals, receptor and downstream signal transduction, cell cycle progression, and epigenetic regulation of gene expression, all of which are significantly affected by increasing age. Studies suggest that circulating growth factors and their receptors are decreased with age, along with important intracellular signaling molecules, such as Pdx-1 and FoxM1. Cell cycle progression is inhibited by an increased expression of cell cycle inhibitors and a reduction in cell cycle kinase complexes (Cyclin/Cdks). Moreover, decreased expression of epigenetic silencers, such as polycomb group proteins, results in derepression of the cell cycle inhibitor p16, and a significant reduction in β-cell proliferation. Collectively, these age-induced changes present obstacles for the design of β-cell regenerative therapies for diabetes; however, some reports suggest that even very old β-cells can re-enter cell cycle. Future studies will further define the effects of aging on β-cell proliferation and elucidate new drug targets for diabetes therapy.

Total Pages: 20-41 (22)

Purchase Chapter  Book Details


.Phytotherapy in the Management of Diabetes and Hypertension.
.Phytotherapy in the Management of Diabetes and Hypertension.
.Frontiers in Clinical Drug Research – Diabetes and Obesity.
.Understanding Obesity: From its Causes to Impact on Life.